No monitoring and measurement effort will be more important to the long-term health of communities than understanding and ...

Health Affairs' Rob Lott interviews Michael T. Osterholm, the director of the Center for Infectious Disease Research and ...

If we are serious about narrowing health gaps, then our environmental protections must be safeguarded against political ...

In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...

We must resist the temptation to reinterpret the Bayh-Dole Act even in an effort to improve the affordability of and access ...

Without policy intervention to address average sales price-based challenges to biosimilar market sustainability, there is a ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...

US v. Skrmetti undermined constitutional guardrails that guarantee rigorous assessment of medical justifications for policies limiting the rights of transgender people and women, creating a need and ...

The No Surprises Act has protected patients from surprise medical bills. However, the law’s incentives for insurers acting as ...

While recent fertility drug-related announcements by the Trump administration could result in savings for women—especially ...

Prior authorization is a barrier to accessing medications for opioid use disorder (MOUD). Although private insurance covered about one-third of patients with OUD in 2023, the understanding of prior ...

Health Affairs' Jeff Byers welcomes Allison Oakes, Chief Research Officer of Trilliant Health, to the pod to discuss ...